BRIEF published on 02/16/2026 at 07:35, 7 months 8 days ago Nicox Receives Positive Feedback from FDA for NCX 470 NDA FDA Nicox Glaucoma Treatment NCX 470 NDA Submission
PRESS RELEASE published on 02/16/2026 at 07:30, 7 months 8 days ago Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470 Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470, confirmant le dépôt de la NDA pour l'été 2026. Collaboration avec Kowa et avancée vers l'autorisation de mise sur le marché FDA Nicox NCX 470 Réunion Pré-NDA Autorisation De Marché
PRESS RELEASE published on 02/16/2026 at 07:30, 7 months 8 days ago Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 Nicox receives positive feedback from pre-NDA meeting with U.S. FDA for NCX 470, on track for NDA submission in summer 2026. NCX 470 lowers intraocular pressure in glaucoma patients FDA Nicox NCX 470 Intraocular Pressure Pre-NDA
BRIEF published on 02/12/2026 at 07:35, 7 months 12 days ago Nicox maintains its PEA-PME status for 2026 PEA-PME Euronext Growth Paris Investment Ophthalmology Nicox
BRIEF published on 02/12/2026 at 07:35, 7 months 12 days ago Nicox maintient son statut PEA-PME pour 2026 PEA-PME Euronext Growth Paris Investissement Ophtalmologie Nicox
PRESS RELEASE published on 02/12/2026 at 07:30, 7 months 12 days ago Nicox confirme son éligibilité au PEA-PME Nicox confirme son éligibilité au PEA-PME pour l'année à venir, permettant aux investisseurs de continuer à intégrer ses actions dans les comptes PEA PME PEA-PME Investissement Fiscalité Ophtalmologie Nicox
BRIEF published on 02/10/2026 at 07:35, 7 months 14 days ago Nicox to Present Key Data at AGS Annual Meeting 2026 Clinical Trials Glaucoma Nicox NCX 470 AGS 2026
BRIEF published on 02/10/2026 at 07:35, 7 months 14 days ago Nicox présentera des données clés lors de la réunion annuelle de l'AGS en 2026. Essais Cliniques Nicox NCX 470 Glaucome AGS 2026
PRESS RELEASE published on 02/10/2026 at 07:30, 7 months 14 days ago Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS) Nicox présente les données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l'AGS, démontrant l'efficacité de leur nouveau produit pour le glaucome Ophtalmologie Nicox NCX 470 Études De Phase 3 Congrès AGS
PRESS RELEASE published on 02/10/2026 at 07:30, 7 months 14 days ago Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Nicox to present NCX 470 Phase 3 data at AGS Annual Meeting 2026 with podium presentations showcasing clinical study results and efficacy of the ophthalmic solution Clinical Study Ophthalmology Nicox NCX 470 AGS Annual Meeting 2026
Published on 09/25/2026 at 00:30, 3 hours 3 minutes ago Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 3 hours 18 minutes ago CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 5 hours 32 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 12 hours 38 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/25/2026 at 02:45, 48 minutes ago Huagui Group: un acteur mondial sur deux marchés aquatiques de plus de 100 milliards de RMB, tandis que la racine de lotus de Honghu se classe au premier rang pour sa teneur en antioxydants
Published on 09/25/2026 at 02:45, 48 minutes ago Huagui Group: A Global Player Across Two RMB100-Billion Aquatic Markets, as Honghu Lotus Root Ranks No. 1 in Antioxidant Content
Published on 09/24/2026 at 20:29, 7 hours 4 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 8 hours 33 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 8 hours 52 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:31, 9 hours 1 minute ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 9 hours 33 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 9 hours 33 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
